MAP3K19 and chronic obstructive pulmonary disease: Having demonstrated that inhibition of MAP3K19 can impact the inflammation observed in a four day acute cigarette smoke model, we next wanted to assess whether we could impact the parenchymal changes in the lung following a five month chronic model of COPD with therapeutic dosing of the animals.